AVITA Medical (RCEL) Fundamental Analysis: Revenue, Earnings & Valuation

2.74 / 10

Underperform

Fundamental analysis rates RCEL as Underperform with a 2.74/10 score. Inventory turnover and cost‑of‑sales are solid, yet long‑term debt, PB‑ROE and asset valuation lag, leading to an overall weak quality rating.

Analysis Checks(7/10)

Revenue-MV

Value-0.06

Score3/3

Weight57.34%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value11.45

Score2/3

Weight0.79%

1M Return0.13%

Inventory turnover ratio

Value1.80

Score3/3

Weight-5.63%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value85.81

Score3/3

Weight10.65%

1M Return1.67%

PB-ROE

Value0.55

Score0/3

Weight19.31%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value6.39

Score1/3

Weight-3.85%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-6.65%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value11.45

Score2/3

Weight0.32%

1M Return0.05%

Cost of sales ratio (%)

Value17.87

Score3/3

Weight1.66%

1M Return0.26%

Asset-MV

Value-0.55

Score0/3

Weight26.06%

1M Return4.00%

Is RCEL undervalued or overvalued?

RCEL scores 2.74/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -67.85% net margin, -2.33 P/E ratio, -6.81 P/B ratio, and 27.20% earnings growth, these metrics solidify its Underperform investment rating.